Novogenia AG, an international healthcare company specializing in human genetics and personalized products, has announced the U.S. launch of its new MGT Plus methylation test. The launch marks a significant step in the company's collaboration with its U.S. partner, 10X Health, as they expand their joint product pipeline and strengthen their international presence in the field of genetic analysis and longevity.
Methylation is a fundamental biochemical process that influences numerous metabolic and regulatory functions in the human body. It plays a critical role in the processing of essential molecules, including vitamins and neurotransmitters. While standard commercial tests often analyze only a limited set of genes, MGT Plus covers a total of 27 genes, providing a more comprehensive picture of methylation processes across six interconnected biological pathways. These pathways include energy and nutrient metabolism, stress and neurotransmitter regulation, as well as vascular, immune, and cellular health. This expanded scope offers more precise insights into key biochemical processes, enabling a deeper understanding of an individual's genetic predispositions.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, highlighted the importance of this launch: "With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health."
The timing of this launch aligns with the rapid growth of the direct-to-consumer genetic testing market. In 2025, the global market size reached approximately $4.7 billion and is projected to exceed $16.0 billion by 2033. Genetic testing currently represents the largest segment, accounting for over 40 percent of the market. North America leads this sector, contributing around 50 percent of the global market volume in 2025. This growth is driven by increasing consumer interest in personalized health information, prevention, and tailored health services.
Novogenia's MGT Plus test is now available in the U.S., offering healthcare providers and consumers a more detailed analysis of methylation-related pathways. By integrating this advanced testing into their offerings, Novogenia and 10X Health aim to support more informed decisions in preventive health and personalized wellness.
For more information about Novogenia and its products, visit https://novogenia.com/novogenia-ag.
